alexa The Prolyl Peptidyl Isomerase Pin1 as a Potential Therapeutic Target in Atherosclerosis | OMICS International
ISSN: 2161-1459
Journal of Clinical & Experimental Pharmacology

Like us on:

Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

The Prolyl Peptidyl Isomerase Pin1 as a Potential Therapeutic Target in Atherosclerosis

Narin Osman and Peter J Little*

Discipline of Pharmacy, School of Medical Sciences and Diabetes Complications Group, Metabolism, Exercise and Disease Program, Health Innovations Research Institute, RMIT University, Melbourne, Victoria 3083 Australia

*Corresponding Author:
Peter J Little
Discipline of Pharmacy
School of Medical Sciences and Diabetes Complications Group
Health Innovations Research Institute
RMIT University
Melbourne, Victoria 3083 Australia
Tel: 61-3-99256686
E-mail: [email protected]

Received date: October 18, 2012; Accepted date: October 21, 2012; Published date: October 24, 2012

Citation: Osman N, Little PJ (2012) The Prolyl Peptidyl Isomerase Pin1 as a Potential Therapeutic Target in Atherosclerosis. Clin Exp Pharmacol 2:e109. doi: 10.4172/2161-1459.1000e109

Copyright: ©2012 Osman N, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Journal of Clinical & Experimental Pharmacology

Atherosclerosis is the major underlying pathology of cardiovascular disease which is in turn the largest cause of premature mortality in developed countries [1]. Rising obesity and diabetes rates are associated with factors that greatly accelerate the development of coronary artery and other macrovascular diseases. The major areas of investigation of atherosclerosis are focused on the initial pre-inflammatory stage in which atherogenic lipoproteins are trapped in the vessel wall by modified proteoglycans, the inflammatory stage in which immune cells penetrate the vessel wall accumulate cholesterol debris and generate atherosclerotic plaques and the final stage in which plaques rupture precipitating the lethal clinical event [2,3]. The initial stage depends upon the action of growth factors to stimulate hyperelongation of chondroitin sulfate/dermatan sulfate glycosaminoglycan (GAG) chains on the small lipid binding proteoglycan biglycan [4]. This is associated in vivo with the elevated expression of GAG synthesizing enzymes in mouse models of atherosclerosis [5]. Transforming Growth Factor (TGF)-β is closely associated with the development of atherosclerosis and it is an important modifier of GAG structure [6,7]. TGF-β signals via serine/threonine phosphorylation of Smad transcription factors [8,9]. This pathway is involved in proteoglycan synthesis in vascular smooth muscle cells [10] and also induces growth in fibroblasts [11]. Phosphorylation of Smad2/3 can occur directly in the carboxy terminus and indirectly in its linker region [12]. These phosphorylation sites in the linker region of Smad2/3 provide potential sites for the action of the prolyl peptidyl isomerase, Pin-1. Pin-1 is being investigated for its potential as a therapeutic target in cancer [13] but it might also in this context be a therapeutic target in cardiovascular disease.

Pin1, a member of theparvulin family of peptidyl prolyl isomerases, has a unique preference for binding via its N-terminal WW domain to phosphorylated-serine/proline or -threonine/proline sequences in proteins. The unique Pin1 C-terminal catalytic domain subsequently catalyses a cis or trans isomerisation of the bound protein. The prolyl isomerisation is a rate-limiting step in protein folding and induces conformational changes, leading to distinct effects in different target proteins, including increased stability or turnover, changes in sensitivity to phosphatases, altered enzymatic activity or subcellular localization, and enabling different ligand protein interactions. Over 30 Pin1 targets have been identified [5,14,15]. Pin1 is overexpressed in many cancers and is associated with transformation and uncontrolled cell growth, Alzheimer’s disease and asthma [14,15]. Pin1 is a significant component of TGF-β signalling. TGF-β signals can regulate cell proliferation, differentiation, migration and apoptosis all known to be important processes in the pathogenesis of atherosclerosis. A role for TGF-β in neointimal hyperplasia of early atherosclerosis is well established [16]. Receptor Smad transcription factors Smad2 and Smad3 are critical signalling components of the TGF-β signal cascade that result in regulation of gene transcription. A Pin1 binding motif in the linker region of Smad3 at threonine residue 179 is phosphorylated by kinases CDK8/9 in response to TGF-β [17] and binds the WW domain of Pin1 to generate maximum transcriptional activity of genes involved in promoting TGF-β mediated migration and invasion [18]. Pin1 is also involved in intimal hyperplasia via regulation of the antioxidant enzyme hemeoxygenase-1 and in vascular smooth muscle proliferation [19]. Overexpression of Pin1 in vascular smooth muscle cells reduces nuclear levels of nuclear factor E2-related factor-2 via induction of ubiquitinylation and thereby decreases the levels of hemeoxygenase-1 and subsequent neointimal formation [19].

Recently it has been shown that Pin1 catalyses protein isomerisation of activated Protein Kinase C (PKC) [11,20]. The pro-atherogenic effects of activated PKC in vascular smooth cells and endothelial cells are well-known. A number of critical cell surface receptor signalling pathways activate PKC including the receptor for endothelin, a G protein coupled receptor and the receptor for PDGF a protein tyrosine kinase receptor. Both receptor signalling cascades lead to atherogenic changes in the extracellular matrix of the blood vessel wall particularly changes to the lipid binding glycosaminoglycan chains of proteoglycans [21,20]. Other important atherogenic vascular changes induced by agonist induced PKC activation include increases in contractility [22], extracellular matrix deposition [23] and cellular hypertrophy and proliferation.Pin1 binding and isomerisation to the trans configuration of activated conventional PKC isozymes results in down-regulation of their PKC expression and activity as a result of ubiquitinylation and degradation. Pin1 acts as a molecular timer to determine the cellular lifetime of the active conventional isozymes, in contrast the novel PKCisozymes are already in the trans configuration and are bypassed by Pin1 [11]. The length of time active PKCisozymes are able to signal will have significant impact on subsequent signalling outputs thereby influencing atherogenic changes in susceptible cells. Pin1 catalysed isomerisation of PKC thus adds an additional post-translation protein modification that significantly impacts on its downstream signalling pathways in concert with the more well-known and fully described phosphorylation and dephosphorylation events. Cis-trans isomerase Pin1 is increasingly being recognised as a key component of growth factor signalling pathways. Pin1 causes important changes in a number of crucial signalling elements and warrants detailed studies of its actions and roles in vascular biology and particularly in the development of atherosclerosis. Its relevance as a potential target in the prevention of the development of atherosclerosis needs to be fully explored.


Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Relevant Topics

Recommended Conferences

  • 12th Asian Biologics and Biosimilars Congress
    August 20-21, 2018 Tokyo, Japan
  • International Conference and Exhibition on Drug Safety & Pharmacovigilance
    August 29-30, 2018 | Toronto, UK
  • 6 th European Biopharma Congress
    September 18-19, 2018 Amsterdam, Netherlands
  • 5th International Conference on Pain Medicine and Pain Management
    October 17-18, 2018 New York, USA
  • 18th World Pharma Congress
    October 18-19, 2018 Warsaw, Poland
  • 13th International Conference on Biosimilars and Biologics
    November 14-15, 2018 Lisbon, Portugal
  • 14th International Conference on Generic Drugs and Biosimilars
    November 15-16, 2018 Berlin, Germany

Article Usage

  • Total views: 11811
  • [From(publication date):
    December-2012 - Jul 16, 2018]
  • Breakdown by view type
  • HTML page views : 8048
  • PDF downloads : 3763

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

+1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals


[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version